

Internationale Publikationen 2010/2011

Randomized Phase III Trial of Sequential Adjuvant Chemoradiotherapy With or Without Erythropoietin Alfa in Patients With High-Risk Cervical Cancer: Results of the NOGGO-AGO Intergroup Study.

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

J Clin Oncol. 2011 Aug 22. [Epub ahead of print]

Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.

du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, Sehouli J. Int J Gynecol Cancer. 2011 Aug;21(6):1165-8.

Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.

Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Özcelik G, Lichtenegger W, Sehouli J. Anticancer Res. 2011 Aug;31(8):2679-82.

Optimizing the clinical management of gynecological and breast cancer via online tumor conferences.

Schroeder JK, Kuemmel S, Pietzner K, Hector J, Sehouli J, Chekerov R. Anticancer Res. 2011 Aug;31(8):2669-73.

First evaluation of the Joint Clinical Registries of the Coordinating Tumor Center of Berlin.

Chekerov R, Braun S, Ebert AD, Herbstreit C, Jagota A, Johannsmeyer KD, Kronenberger C, Potenberg J, Scharf JP, Richter R, Ulrich U, Sehouli J.

Anticancer Res. 2011 Aug;31(8):2657-60.

Prognostic significance of the angiogenic factors angiogenin, endoglin and endostatin in cervical cancer.

Landt S, Mordelt K, Schwidde I, Barinoff J, Korlach S, Stöblen F, Lichtenegger W, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2651-5.

The utility of an in vitro angiogenesis score for prognosis assessment in patients with cervical cancer.

Landt S, Heidecke H, Reuter C, Korlach S, Blohmer JU, Lichtenegger W, Heusner T, Stöblen F, Thill M, Barinoff J, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2645-9.

In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer.

Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Thill M, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2609-15.

CT-guided high-dose-rate brachytherapy of metachronous ovarian cancer metastasis to the liver: initial experience.

Collettini F, Poellinger A, Schnapauff D, Denecke T, Wust P, Braicu IE, Sehouli J, Hamm B, Gebauer B.

Anticancer Res. 2011 Aug;31(8):2597-602.

Prognostic significance of angiogenic factors in uterine cervical cancer.

Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stöblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2589-95.

High-frequency breast ultrasound for the detection of microcalcifications and associated masses in BI-RADS 4a patients.

Stöblen F, Landt S, Ishaq R, Stelkens-Gebhardt R, Rezai M, Skaane P, Blohmer JU, Sehouli J, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2575-81.

First evaluation of the diagnostic accuracy of an automated 3D ultrasound system in a breast screening setting.

Stöblen F, Landt S, Stelkens-Gebhardt R, Sehouli J, Rezai M, Kümmel S.

Anticancer Res. 2011 Aug;31(8):2569-74.

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.

Noske A, Schwabe M, Weichert W, Darb-Esfahani S, Buckendahl AC, Sehouli J, Braicu EI, Budczies J, Dietel M, Denkert C.

BMC Cancer. 2011 Jul 14;11:294.

Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.

Sehouli J, Alfaro V, González-Martín A. Ann Oncol. 2011 Jul 6. [Epub ahead of print]

Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: A phase IIa study of the AGO Study Group. Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, Loibl S, Sehouli J, Huober J, Schmalfeldt B, Vergote I, Lück HJ, Wagner U.

Gynecol Oncol. 2011 Oct;123(1):27-32. Epub 2011 Jul 5.

First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report.

Pietzner K, Jäger M, Schoberth A, Oskay-Özcelik G, Kuhberg M, Lindhofer H, Sehouli J. *Med Oncol*. 2011 May 5. [Epub ahead of print]

Clinical trials in recurrent ovarian cancer. Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2011 May;21(4):771-5.

The involvement of retroperitoneal lymph nodes in primary serous-papillary peritoneal carcinoma. a systematic review of the literature.

Steinhagen PR, Sehouli J.

Anticancer Res. 2011 Apr;31(4):1387-94. Review.

Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort.

Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Tropé CG, Ayhan A, Cormio G, Xing Y, Wollschlaeger KM, Braicu EI, Rabbitt CA, Oksefjell H, Tian WJ, Fotopoulou C, Pfisterer J, du Bois A, Berek JS.

Br J Cancer. 2011 Aug 30. doi: 10.1038/bjc.2011.328. [Epub ahead of print]

Long term combination treatment with bevacizumab, pegylated liposomal doxorubicin and regional abdominal hyperthermia in platinum refractory ovarian cancer: a case report and review of the literature.

Pietzner K, Schmuck RB, Fotopoulou C, Gellermann J, Ismaeel F, Cho CH, Kalden M, Sehouli J.

Anticancer Res. 2011 Aug;31(8):2675-7. Review.

Systemic changes of tryptophan catabolites via the indoleamine-2,3-dioxygenase pathway in primary cervical cancer. Fotopoulou C, Sehouli J, Pschowski R, VON Haehling S, Domanska G, Braicu EI, Fusch G, Reinke P, Schefold JC.

Anticancer Res. 2011 Aug;31(8):2629-35.

First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer.

Papanikolaou G, Fotopoulou C, Braicu I, Chekerov R, Schmidt SC, Pietzner K, Sehouli J.

Anticancer Res. 2011 Aug;31(8):2603-8.

Predictive factors in relapsed ovarian cancer for complete tumor resection.

Gil-Ibáñez B, Oskay-Özcelik G, Richter R, Fotopoulou C, Braicu EI, Neuhaus P, Lichtenegger W, Sehouli J; Tumor Bank Ovarian Cancer Network (TOC); European Competence Centre for Ovarian Cancer (EKZE Berlin).

Anticancer Res. 2011 Aug;31(8):2583-7.

Primary versus secondary cytoreduction for epithelial ovarian cancer: A paired analysis of tumour pattern and surgical outcome.

Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C.

Eur J Cancer. 2011 Jul 12. [Epub ahead of print]

A Risk Model for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: An Evidence-Based Proposal for Patient Selection.

Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, Cormio G, Xing Y, Breitbach GP, Braicu EI, Rabbitt CA, Oksefjell H, Fotopoulou C, Meerpohl HG, du Bois A, Berek JS, Zang RY, Harter P.

Ann Surg Oncol. 2011 Jul 6. [Epub ahead of print]

Correlation of midtrimester amniotic fluid cytokine concentrations with adverse pregnancy outcome in terms of spontaneous Abortion, preterm birth, and preeclampsia.

Bamberg C, Fotopoulou C, Thiem D, Roehr CC, Dudenhausen JW, Kalache KD.

J Matern Fetal Neonatal Med. 2011 Jul 5. [Epub ahead of print]

Mid-trimester amniotic fluid concentrations of the proinflammatory cytokines IL-6, IL-8, TNF- α , and lipopolysaccharide binding protein in normal pregnancies: a prospective evaluation according to parity, gestational age, and fetal gender.

Bamberg C, Fotopoulou C, Linder M, Roehr CC, Dudenhausen JW, Henrich W, Kalache K.

J Perinat Med. 2011 Jul;39(4):403-9. Epub 2011 Jun 24.

Polo-like kinase PLK 2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.

Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Slozarek P, McNeish IA, Blagden S, Schmid P, Lovell DP, Hatzmichael E, Crook T.

Cancer Res. 2011 Mar 14. [Epub ahead of print]

Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking.

Fotopoulou C, Richter R, Braicu EI, Kuhberg M, Feldheiser A, Schefold JC, Lichtenegger W, Sehouli J.

Ann Surg Oncol. 2011 Mar 11. [Epub ahead of print]

Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.

Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C.

Oncol Rep. 2011 Apr;25(4):1005-12. doi: 10.3892/or.2011.1162. Epub 2011 Jan 25.

Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.

Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, Mahner S, Vergote I, Reinthaller A, Burges A, Hanker L, Pölcher M, Kurzeder C, Canzler U, Petry KU, Obermair A, Petru E, Schmalfeldt B, Lorusso D, du Bois A.

Int J Gynecol Cancer. 2011 Feb;21(2):289-95.

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.
BMC Cancer. 2010 Dec 3;10:666.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G.
J Clin Oncol. 2011 Jan 10;29(2):242-8. Epub 2010 Nov 29.

An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.

Wynendaele J, Böhnke A, Leucci E, Nielsen SJ, Lambertz I, Hammer S, Sbrzesny N, Kubitza D, Wolf A, Gradhand E, Balschun K, Braicu I, Sehouli J, Darb-Esfahani S, Denkert C, Thomssen C, Hauptmann S, Lund A, Marine JC, Bartel F.
Cancer Res. 2010 Dec 1;70(23):9641-9. Epub 2010 Nov 16.

Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis.

Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C.
Int J Gynecol Cancer. 2010 Nov;20(8):1331-40.

What are the individual perceptions of patients with borderline tumours of the ovary in regard to pathogenesis and prognosis? A structured survey on 60 women.

Fotopoulou C, Bugariu M, Braicu EI, Lichtenegger W, Sehouli J.
J Psychosom Obstet Gynaecol. 2010 Dec;31(4):265-72. Epub 2010 Nov 2.

Use of paclitaxel for advanced ovarian cancer in clinical practice: analysis of 541 patients. Results from a German multi-centre observational study.

Sehouli J, Oskay-Ozelik G.
Anticancer Res. 2010 Oct;30(10):4245-50.

Epigenetic quantification of tumor-infiltrating T-lymphocytes.

Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmüller U, Grützkau A, Lohneis P, Dickhaus T, Gröne J, Kruschewski M, Mustea A, Turbachova I, Baron U, Olek S.
Epigenetics. 2011 Feb 1;6(2):236-46. Epub 2011 Feb 1.

Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.

Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J.
Eur J Surg Oncol. 2010 Dec;36(12):1202-10. Epub 2010 Sep 22.

Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients.

Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C.
J Surg Oncol. 2010 Nov 1;102(6):656-62.

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.

du Bois A, Herrstedt J, Hardy-Bessard AC, Müller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J.
J Clin Oncol. 2010 Sep 20;28(27):4162-9. Epub 2010 Aug 23.

Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.

Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J.
Ann Surg Oncol. 2011 Jan;18(1):49-57. Epub 2010 Aug 10.

Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report.

Schmuck RB, Pietzner K, Buckendahl A, Schönlebe J, Sehouli J.
Anticancer Res. 2010 Jul;30(7):2991-4.

Expression and localization of e-cadherin in epithelial ovarian cancer.

Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J.
Anticancer Res. 2010 Jul;30(7):2525-30.

Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome.

Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, Sehouli J.
Gynecol Oncol. 2010 Nov;119(2):285-90. Epub 2010 Jul 15.

Clinical management of borderline tumours of the ovary - experience from the "Berlin online tumour conference for gynaecological malignancies".

Sehouli J, Oskay-Oezcelik G, Pietzner K, Chen F, Coumbos A, Darb-Esfahani S, Schuback B, Heinrich G, Kronenberger C, Lorsbach M, Lichtenegger W, Chekerov R.
Anticancer Res. 2010 May;30(5):1701-6.

Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma.
Darb-Esfahani S, Sinn BV, Weichert W, Budczies J, Lehmann A, Noske A, Buckendahl AC, Müller BM, Sehouli J, Koensgen D, Györfy B, Dietel M, Denkert C.
Histopathology. 2010 May;56(6):727-39.

External iliac artery ligation due to late postoperative rupture after radical lymphadenectomy for advanced ovarian cancer--two case reports.
Fotopoulou C, Neumann U, Kraetschell R, Lichtenegger W, Sehouli J.
Eur J Gynaecol Oncol. 2010;31(2):198-200.

Atypical protein kinase C zeta exhibits a proapoptotic function in ovarian cancer.
Nazarenko I, Jenny M, Keil J, Gieseler C, Weisshaupt K, Sehouli J, Legewie S, Herbst L, Weichert W, Darb-Esfahani S, Dietel M, Schäfer R, Ueberall F, Sers C.
Mol Cancer Res. 2010 Jun;8(6):919-34. Epub 2010 May 25.

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, GebSKI V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A.
J Clin Oncol. 2010 Jul 10;28(20):3323-9. Epub 2010 May 24.

Reconstructive surgical management of cryptomenorrhoea because of complex uterovaginal malformations with duplicate uterus and complete vaginal agenesis.
Fotopoulou C, Gehrman N, Sehouli J, Lichtenegger W.
Fertil Steril. 2010 Nov;94(6):2329.e13-6. Epub 2010 May 5.

Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.
Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalifaoui K, Oskay-Ozcelik G.
Ann Oncol. 2010 Nov;21(11):2201-5. Epub 2010 May 3.

. Technical performance of lactate biosensors and a test-strip device during labour.
Luttikus AK, Fotopoulou C, Sehouli J, Stupin J, Dudenhausen JW.
Z Geburtshilfe Neonatol. 2010 Apr;214(2):62-7. Epub 2010 Apr 21.

Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies.
Fotopoulou C, Neumann U, Kraetschell R, Schefold JC, Weidemann H, Lichtenegger W, Sehouli J.
J Surg Oncol. 2010 May 1;101(6):507-12.

European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies.

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J, Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A, Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups.

Int J Gynecol Cancer. 2010 Apr;20(3):476-8. No abstract available.

Tumor-specific correlation of tumor M2 pyruvate kinase in pre-invasive, invasive and recurrent cervical cancer.

Landt S, Jeschke S, Koeninger A, Thomas A, Heusner T, Korlach S, Ulm K, Schmidt P, Blohmer JU, Lichtenegger W, Sehouli J, Kuemmel S.

Anticancer Res. 2010 Feb;30(2):375-81.

BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.

Pils D, Wittinger M, Petz M, Gugerell A, Gregor W, Alfan A, Horvat R, Braicu EI, Sehouli J, Zeillinger R, Mikulits W, Krainer M.

Gynecol Oncol. 2010 May;117(2):189-97. Epub 2010 Feb 26.

[Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].

Sehouli J, Goertz A, Steinle T, Dubois R, Plesnila-Frank C, Lalla A, von Minckwitz G.

Dtsch Med Wochenschr. 2010 Mar;135(9):385-9. Epub 2010 Feb 23. German.

Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study.

Fotopoulou C, Hee Cho C, Kraetschell R, Gellermann J, Wust P, Lichtenegger W, Sehouli J.

Int J Hyperthermia. 2010;26(2):118-26.

Primary radical surgery in elderly patients with epithelial ovarian cancer: analysis of surgical outcome and long-term survival.

Fotopoulou C, Savvatis K, Steinhagen-Thiessen E, Bahra M, Lichtenegger W, Sehouli J.

Int J Gynecol Cancer. 2010 Jan;20(1):34-40.

Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status.

Fotopoulou C, Savvatis K, Kraetschell R, Schefold JC, Lichtenegger W, Sehouli J.

Eur J Obstet Gynecol Reprod Biol. 2010 Apr;149(2):199-203. Epub 2010 Jan 22.

A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer.
Sehouli J, Camara O, Mahner S, Bauknecht T, Lichtenegger W, Runnebaum I, Look K, Jaenicke F, Oskay-Oezcelik G.
Cancer Chemother Pharmacol. 2010 Oct;66(5):861-8. Epub 2010 Jan 7.

Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
Faggad A, Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Müller BM, Wirtz R, Chekerov R, Weichert W, Sinn B, Mucha C, Elwali NE, Schäfer R, Dietel M, Denkert C.
J Pathol. 2010 Feb;220(3):382-91.

Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology.
Oskay-Ozcelik G, Chekerov R, Sommer H, Keil E, Einkenkel J, Pfisterer J, Lorenz-Schlüter C, Lichtenegger W, Camara O, Sehouli J.
Gynecol Oncol. 2010 Mar;116(3):317-22. Epub 2009 Dec 2.

Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary.
Fotopoulou C, Schumacher G, Schefold JC, Denkert C, Lichtenegger W, Sehouli J.
Int J Gynecol Cancer. 2009 Dec;19(9):1550-5.

Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Vergote I, Amant F, Oskay-Oezcelik G, Musib L, Michel AL, Darstein C, Kania M, Bauknecht T, Sehouli J.
Int J Gynecol Cancer. 2009 Dec;19(9):1505-10.

ABC transporter gene expression in benign and malignant ovarian tissue.
Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R.
Gynecol Oncol. 2010 May;117(2):198-201. Epub 2009 Nov 17.

Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: results of a phase I and II study.
Koensgen D, Oskay-Oezcelik G, Katsares I, Walle U, Klapp C, Mustea A, Stengel D, Porzolt F, Lichtenegger W, Sehouli J; Nord-Ostdeutschen Gesellschaft für Gynäkologische Onkologie (NOGGO) working group "Quality of life".
Support Care Cancer. 2010 Aug;18(8):931-42. Epub 2009 Sep 17.

Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Fotopoulou C, Baumunk D, Schmidt SC, Schumacher G.

Anticancer Res. 2010 Nov;30(11):4619-24.

High-mobility group box-1 protein serum levels do not reflect monocytic function in patients with sepsis-induced immunosuppression.

Unterwalder N, Meisel C, Savvatis K, Hammoud B, Fotopoulou C, Volk HD, Reinke P, Schefold JC.

Mediators Inflamm. 2010;2010:745724. Epub 2010 Jun 21.

Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.

Schefold JC, Zeden JP, Pschowski R, Hammoud B, Fotopoulou C, Hasper D, Fusch G, Von Haehling S, Volk HD, Meisel C, Schütt C, Reinke P.

Scand J Infect Dis. 2010 Mar;42(3):164-71.